Synonyms: Camzyos® | MYK-461 | MYK461
mavacamten is an approved drug (FDA (2022), EMA (2023))
Compound class:
Synthetic organic
Comment: Mavacamten (MYK-461) is an orally active myosin allosteric modulator [1] that was developed by MyoKardia as a novel treatment for obstructive hypertrophic cardiomyopathy (HCM). In 2020 MyoKardia was bought by Bristol Myers Squibb. The compound interacts with both α and β cardiac myosins in vitro. Preclinical pharmacokinetics are reported in [2]. Mavacamten attenuates hypertrophic and profibrotic gene expression in rodent models of HCM [1].
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02842242 | A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction | Phase 2 Interventional | MyoKardia, Inc. | 3 | |
NCT02480296 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers | Phase 1 Interventional | MyoKardia, Inc. | 3 | |
NCT03723655 | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM | Phase 2/Phase 3 Interventional | MyoKardia, Inc. | 3 | |
NCT04349072 | A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy | Phase 3 Interventional | MyoKardia, Inc. | 3 | |
NCT03470545 | Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 Interventional | MyoKardia, Inc. | Analysis of data collected from this study (the EXPLORER-HCM study) showed that mavacamten suppressed disease-specific symptoms and improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy. | 3-4 |